Sandoz announces changes in the Board of Directors
01 févr. 2024 01h15 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Graeme Pitkethly nominated as candidate for election to the Sandoz Board of Directors at the upcoming Annual...
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
31 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Tyruko® approved for all indications of reference medicine Tyruko® biosimilar to treat...
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
22 janv. 2024 01h00 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**...
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
21 nov. 2023 01h00 HE
|
Sandoz Group
Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across...
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
10 nov. 2023 08h02 HE
|
Sandoz Group
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicinesNew penicillin production process will significantly improve ecological footprint and help...
Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
08 nov. 2023 12h46 HE
|
Sandoz Group
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600...
Sandoz successfully issues CHF 750 million in inaugural bonds
26 oct. 2023 11h45 HE
|
Sandoz Group
Highly successful inaugural CHF senior bonds priced earlier todayTwo tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons,...
Sandoz reports year-to-date sales for the first nine months of 2023
24 oct. 2023 01h15 HE
|
Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1)Solid performance in Generics;...
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
04 oct. 2023 01h05 HE
|
Sandoz Group
Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indicesStandalone Sandoz committed to extend leadership in stable...